Immunovant (IMVT) Current Assets (2018 - 2026)

Immunovant's Current Assets history runs 9 years deep, the most recent figure standing at $948.8 million for Q1 2026.

• Quarterly Current Assets rose 23.6% year-over-year to $948.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $948.8 million (up 23.6% YoY) and the FY2026 annual result came in at $948.8 million, up 23.6% from the prior year.
• Current Assets was $948.8 million for Q1 2026 at Immunovant, down from $1.0 billion in the prior quarter.
• Across five years, Current Assets topped out at $1.0 billion in Q4 2025 and bottomed at $291.2 million in Q3 2023.
• A 5-year average of $574.4 million and a median of $512.9 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets tumbled 41.96% — and 2025, when it jumped 152.81%.
• Immunovant's Current Assets stood at $454.4 million in 2022, then jumped by 56.41% to $710.8 million in 2023, then tumbled by 41.96% to $412.5 million in 2024, then soared by 152.81% to $1.0 billion in 2025, then fell by 9.02% to $948.8 million in 2026.
• Business Quant data shows IMVT's Current Assets at $948.8 million in Q1 2026, $1.0 billion in Q4 2025, and $573.5 million in Q3 2025.